It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Discover weekend jobs for quick cash that can help you earn extra income while enjoying your time off. Take the first step to financial freedom today!
20,496 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A major investor moved a sizable stake in Hinge Health, triggering questions about timing and motives. This analysis ...
SBI Holdings, Ripple’s biggest shareholder outside the United States, is quietly developing institutional XRP lending...
Investors gauge SpaceX’s potential public listing amid a cautious IPO market. History from Meta’s debut suggests hype...
Investors rushed to understand why intuitive surgical stock dropped this week. This article dissects the catalysts, g...
Strategy continues to deploy capital into Bitcoin as market dynamics evolve, highlighting the tension between bold cr...
Wayfair reported a quarterly loss and warned margins could shrink as it accelerates expansion. Investors responded wi...
Public disputes can hit more than pride—they touch brand value and bank balances. Learn how chris brown avoids “inter...
Snap once soared to a record high, but the stock now sits well below that peak. This article breaks down the recovery...
Investors are torn over a high-growth AI stock. This article breaks down the split, lays out the bull case, and shows...
Four high-profile tech names have shed 23% to 37% in 2026 as the Nasdaq edges higher. Analysts see substantial upside...
The spotlight isn’t only on SCHD. Schwab’s international dividend ETF SCHY is quietly stealing the show for investors...